Shots:

• Schrödinger to receive up front to fund the share of research costs & is also eligible to receive ~$338M in pre/ clinical- regulatory & sales-based milestones along with royalties on sales outside the US
• Zai will be responsible for the global development- manufacturing- and commercialization of the selected candidates. Schrödinger will be eligible for 50% of the profits from the commercialization of the therapy if it elects to co-fund the candidate emerges under collaboration
• Schrödinger to get co-development and co-commercialization rights in the US. Additionally- each company will be responsible for its research program expenses

  | Ref: Businesswire | Image: Trading View